Physician profile
John Michael Bernardi
NPI 1376730275
$6,614.05
in general payments reported to CMS, 2019-2025
30 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $637 · 2021: $762 · 2022: $1,204 · 2023: $1,088 · 2024: $1,131 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,118.84 |
| Education | $128.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,531.47 | 2019-2024 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,008.08 | 2019-2025 | |
| Janssen Biotech, INC. | $940.50 | 2019-2025 | Tremfya |
| Ucb, INC. | $509.10 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $467.72 | 2019-2025 | Winlevi, Absorica Ld, Odomzo |
| E.R. Squibb & Sons, L.L.C. | $410.41 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $290.03 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $275.82 | 2019-2025 | |
| Genzyme Corporation | $188.41 | 2019-2025 | |
| Amgen INC. | $180.09 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $130.23 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $127.29 | 2019-2025 | Aklief, Nemluvio |
| Arcutis Biotherapeutics, INC. | $99.33 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 | |
| Lilly USA, LLC | $61.11 | 2019-2023 | Taltz, Olumiant |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $38.39 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.41 | 2019-2021 | |
| Celgene Corporation | $30.03 | 2019 | |
| Incyte Corporation | $29.46 | 2021-2023 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $29.20 | 2022-2023 | Valchlor |
| Journey Medical Corporation | $23.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.84 | 2022 | |
| Stemline Therapeutics INC. | $18.36 | 2020 | |
| Genentech USA, INC. | $17.48 | 2021 | |
| Sebela Pharmaceuticals INC. | $16.01 | 2023 | Naftin, Pramosone |
| Organon LLC | $13.84 | 2025 | Vtama |
| Kyowa Kirin, INC. | $13.30 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Encore Dermatology INC. | $11.56 | 2020 | |
| Biofrontera INC. | $6.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bernardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.